Novel Compounds for Treatment of Parasitic Infections (2019-019)

Novel compounds that target trypanosomiasis and other devastating parasitic infections

Market Overview

African Trypanosomiasis, also known as “sleeping sickness,” is caused by microscopic parasites transmitted to humans by the Tsetse fly, found in rural Africa. It is a serious public health problem in sub-Saharan Africa, with around 10,000 new cases each year. This serious disease is fatal if left untreated, however, the currently available treatments are incredibly difficult to administer, and can be extremely toxic to the patient. Melarsoprol, one of the primary drugs used to treat late stage disease, is an arsenic derivative that is lethal to around 5% of patients who receive it. The global market for treatment of neglected tropical diseases was valued at $1.2 billion in 2018 and is expected to rise to $2.6 billion by 2021. The patient need, combined with global warming increasing the spread of tropical diseases north and southward, has created a strong demand for new solutions. Clemson researchers have developed novel compounds that are active against this devastating pathogen, offering an avenue for dramatically improved treatment.

Technical Summary

These compounds are diazocyclobutenes, synthesized via a novel and simple method, and could potentially be active against many different diseases. The compounds are currently demonstrated to be efficacious against *Trypanosoma brucei*, and have a superior safety profile to some of the currently available drugs. They are active in the nano- to micro-molar range, which is crucial for the development of a pharmaceutical, and although the structure-function relationship is not well understood, they are non-toxic to mammalian cells, a drastic improvement over the arsenic-derived compounds currently used to treat the disease.
<table>
<thead>
<tr>
<th>App Type</th>
<th>Country</th>
<th>Serial No.</th>
<th>Patent No.</th>
<th>CURF Ref. No.</th>
<th>Inventors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provisional</td>
<td>United States</td>
<td>62/817,150</td>
<td>NA</td>
<td>2019-019</td>
<td>Dr. Daniel Whitehead</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dr. Jim Morris</td>
</tr>
</tbody>
</table>

### About the Inventors

**Dr. Daniel Whitehead**  
Associate Professor of Chemistry at Clemson University  
Dr. Daniel Whitehead received his Ph.D. from Michigan State University for Chemistry in 2009. From 2009-2011, he was a postdoctoral fellow at North Carolina State University. Dr. White is also the Chemistry Undergraduate Program Coordinator at Clemson. His research centers on new reaction methodology, focusing mainly on new oxidation methods, as well as materials chemistry and bio-inorganic chemistry.

**Dr. Jim Morris**  
Professor of Genetics and Biochemistry at Clemson University  
Dr. Jim Morris received his Ph.D. from the University of Georgia for Cellular Biology in 1997. He is the lead researcher for the Laboratory of Protozoan Parasite Nutrient Sensing at Clemson. Dr. Morris’ research focuses on T. brucei and how the parasite responds to changes in environmental glucose availability, as well as exploring novel drug targets.

---

**Chris Geisswein**  
Director of Licensing  
E: agesswe@clemson.edu  
P: (864) 656-0797

For more information on this technology contact: